TH148141A - Combination of estradiolvalerate or estradiol with dienogest for oral therapy in malfunctioning uterine bleeding In combination with oral contraceptives - Google Patents

Abstract

DC60 (28/02/60) discloses the use of oestradiol valerate or estradiol in conjunction with 17 alpha-cyanomethyl-17 beta-hydroxystra-4,9-diene-3-transfer (Dienogest) (17-alpha-cyanomethyl- 17 beta-hydroxyoestra-4,9-diene-3-one (dienogest)) to obtain a multicomponent combined drug preparation. For oral treatment of abnormal uterine bleeding, in combination with oral contraceptives. Estradiol Valerate-Dienogest Aggregates or Estradiol-Dienogest Aggregates consists of the first part, containing two drugs per day of 3. mg of estradiolvalerate or less than 3 mg of estradiol, the second part, containing two different sets of the daily dose, of which the first is included. Five daily doses of the total compound of 2 mg of estradiol valerate, or less than 2 mg of estradiol and 2 mg of diogenesis, and the second set comprises 17. The total daily dose of 2 mg of estradiolvalerate or less than 2 mg of estradiol and 3 mg of third part diogen, with two doses. Daily dose of 1 mg of estradiol valerate or less than 1 mg of estradiol. And the other one, with two doses Per day of a pharmaceutical placebo acceptable The total number of pharmacologically acceptable daily dose units of a combination, multipart, and placebo corresponds to a 28-day treatment interval. Is at least one round And depends on the contraceptive needs of the patient being considered. 28/02/2017 Revealed the use of oestradiol valerate or estradiol in combination with 170 (formula) -cyanomethyl-17 (formula) -hydroxystra-4,9-diene-3-transfer (Dienogest) (17 (formula) -cyanomethyl- 17 (formulation) -hydroxyoestra-4,9-diene-3-one (dienogest)) to obtain a multi-component drug-acting preparation. For oral treatment of abnormal uterine bleeding, in combination with oral contraceptives. Estradiol Valerate-Dienogest or Estradiol-Dienogest Combination consists of the first part, containing two daily doses of 3. mg of estradiolvalerate or less than 3 mg of estradiol, the second part, containing two different sets of the daily dose, of which the first is included. Five daily dosing of the total substance of 2 mg of estradiol valerate or less than 2 mg of estradiol and 2 mg of dienogest, and the second package is included. 17 total daily dose of 2 mg of estradiol valerate or less than 2 mg of estradiol and 3 mg of third part diogen, containing two The daily dose of 1 mg of estradiolvalerate or less than 1 mg of estradiol. And the other one, with two doses Per day of a pharmaceutical placebo acceptable The total number of pharmacologically acceptable daily dose units of a combination, multipart, and placebo corresponds to a 28-day treatment interval. Is at least one round And it depends on the contraceptive needs of the patient being considered. -------------------------- revealed the use of estradiol valerate Or estradiol together with 17 alpha-cyanomethyl-17 beta-hydroxystra-4,9-dien-3-transfer (Dienogest) to obtain a drug that is used together. Multi-stage For oral treatment of intrauterine hemorrhage due to dysfunction, in combination with oral contraceptives. The estradiol valerate-dienogest combination or the estradiol-dienogest combination consists of a first step, with two sizes. A daily dose of 3 mg of estradiolvalerate or less than 3 mg of estradiol, a second stage, with two different sets of daily dosing, The first package contains five daily doses of concomitant use of 2 mg of estradiol valerate or less, 2 mg of estradiol and 2 mg of dienosase. The second set, and the second set, consisted of 17 daily doses of concomitant use of 2 mg of estradiolvalerate or less, 2 mg of estradiol and 3 mg of estradiol. Inojest The third step, with two daily doses of 1 mg of estradiolvalerate or less than 1 mg of estradiol, and another step, with two doses. Per day of a pharmaceutical placebo acceptable Total number of daily dose units of multi-step concomitant use. And a placebo acceptable Pharmacy corresponds to 28 days, the duration of treatment is at least one cycle. And depending on The contraceptive needs of patients considering drug patents.

Claims (1)

: DC60 (28/02/60) revealed the use of oestradiol valerate or estradiol in combination with 17 alpha-cyanomethyl-17 beta-hydroxystra-4,9-diene-3-transfer (Dienogest) (17-alpha-cyanomethyl- 17 beta-hydroxyoestra-4,9-diene-3-one (dienogest)) to obtain a multicomponent combined drug preparation. For oral treatment of abnormal uterine bleeding, in combination with oral contraceptives. Estradiol Valerate-Dienogest Aggregates or Estradiol-Dienogest Aggregates consists of the first part, containing two drugs per day of 3. mg of estradiolvalerate or less than 3 mg of estradiol, the second part, containing two different sets of the daily dose, of which the first is included. Five daily doses of the total compound of 2 mg of estradiol valerate, or less than 2 mg of estradiol and 2 mg of diogenesis, and the second set comprises 17. The total daily dose of 2 mg of estradiolvalerate or less than 2 mg of estradiol and 3 mg of third part diogen, with two doses. Daily dose of 1 mg of estradiol valerate or less than 1 mg of estradiol. And the other one, with two doses Per day of a pharmaceutical placebo acceptable The total number of pharmacologically acceptable daily dose units of a combination, multipart, and placebo corresponds to a 28-day treatment interval. Is at least one round And depends on the contraceptive needs of the patient being considered. 28/02/2017 Revealed the use of oestradiol valerate or estradiol in combination with 170 (formula) -cyanomethyl-17 (formula) -hydroxystra-4,9-diene-3-transfer (Dienogest) (17 (formula) -cyanomethyl- 17 (formulation) -hydroxyoestra-4,9-diene-3-one (dienogest)) to obtain a multi-component drug-acting preparation. For oral treatment of abnormal uterine bleeding, in combination with oral contraceptives. Estradiol Valerate-Dienogest or Estradiol-Dienogest Combination consists of the first part, containing two daily doses of 3. mg of estradiolvalerate or less than 3 mg of estradiol, the second part, containing two different sets of the daily dose, of which the first is included. Five daily dosing of the total substance of 2 mg of estradiol valerate or less than 2 mg of estradiol and 2 mg of dienogest, and the second package is included. 17 total daily dose of 2 mg of estradiol valerate or less than 2 mg of estradiol and 3 mg of third part diogen, containing two The daily dose of 1 mg of estradiolvalerate or less than 1 mg of estradiol. And the other one, with two doses Per day of a pharmaceutical placebo acceptable The total number of pharmacologically acceptable daily dose units of a combination, multipart, and placebo corresponds to a 28-day treatment interval. Is at least one round And it depends on the contraceptive needs of the patient being considered. -------------------------- revealed the use of estradiol valerate Or estradiol together with 17 alpha-cyanomethyl-17 beta-hydroxystra-4,9-dien-3-transfer (Dienogest) to obtain a drug that is used together. Multi-stage For oral treatment of intrauterine hemorrhage due to dysfunction, in combination with oral contraceptives. The estradiol valerate-dienogest combination or the estradiol-dienogest combination consists of a first step, with two sizes. A daily dose of 3 mg of estradiolvalerate or less than 3 mg of estradiol, a second stage, with two different sets of daily dosing, The first package contains five daily doses of concomitant use of 2 mg of estradiol valerate or less, 2 mg of estradiol and 2 mg of dienosase. The second set, and the second set, consisted of 17 daily doses of concomitant use of 2 mg of estradiolvalerate or less, 2 mg of estradiol and 3 mg of estradiol. Inojest The third step, with two daily doses of 1 mg of estradiolvalerate or less than 1 mg of estradiol, and another step, with two doses. Per day of a pharmacologically acceptable placebo Total number of daily dose units of multi-step concomitant use. And a placebo acceptable Pharmacy corresponds to 28 days, the duration of treatment is at least one cycle. And depending on The contraceptive needs of the patient considering the claim (Item one) which will appear on the advertisement page: edit 28/02/2017 1. Multipartase compound containing 28 daily doses of oestradiol valerate (oestradiol valerate) with 17 (formulation) - cyanomethyl-17 ( Formula) -hydroxyestra-4,9-diene-3-transfer (dienogest) (17 (formula) -cyanomethyl-17 (formula) -hydroxyestra-4,9-diene. -3-one (dienogest)), consisting of the first part, containing two daily doses of 3 mg of estradiolvalerate, tagged: drug patent